Navigation Links
New Clinical Study Results Indicate Higher Early Virologic Response,with Celgosivir Combination Therapy in HCV Non-Responders

d interferon and ribavirin. Only 7 of the 57 patients entering the study dropped out prior to week 12.

Under the terms of the Agreement, Schering supplied PEGETRON(TM) (peginterferon alfa-2b powder for solution plus ribavirin 200 mg capsules) as well as certain technical and laboratory support and other services for MIGENIX's celgosivir Phase II combination study in chronic HCV patients and a related extension protocol. In addition, the Agreement granted Schering limited periods of exclusivity for data review of clinical trial results and for the negotiation of a license agreement. With the new top-line results, we will be working to provide a data package to Schering over the next few weeks, after which Schering's limited period of exclusivity for data review under the Agreement will commence. No license terms have been negotiated with Schering to date.

Celgosivir is an alpha-glucosidase I inhibitor and is currently the only anti-HCV drug in clinical development that acts on host-directed glycosylation. In preclinical studies, celgosivir has shown excellent in vitro synergy with various interferons in the clinic or in development including Pegasys, PEG-Intron, Infergen, Alferon and IFN-omega (with or without ribavirin) and other drugs in development for the treatment of HCV (e.g. polymerase inhibitors) and therefore has the potential to be included as part of many combination therapeutic approaches to improve efficacy in anti-HCV therapy.

HCV, the most common chronic blood-borne infection in the United States, causes inflammation of the liver and may progress to more serious complications such as cirrhosis of the liver, liver cancer and death. Approximately 2.7 million people in the United States are chronically infected with HCV, and the Centers for Disease Control and Prevention (CDC) estimates that by the year 2010, the number of deaths attributed annually to HCV could surpass that due to HIV/AIDS in the US. Worldwide, the World Health Organ
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Genetic Analysis Systems Enter the Clinical Mainstream
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Large Geographic Differences in EpiPen Prescriptions in the U.S., From the Journal of Allergy and Clinical Immunology
4. Clinical Data Suggest Decreased Bleeding Risk in People With Severe Hemophilia A While Maintaining Factor VIII Levels Above One Percent
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
7. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
11. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
Post Your Comments:
(Date:10/10/2008)... WALTHAM, Mass., Oct. 10 /PRNewswire-FirstCall/...A ), a leading provider of near-patient,diagnostic... yesterday with,Ban Ki-moon, the Secretary-General...or executives of seventeen of the world,s leading,...nostic companies.,Inverness, together with senior ...
(Date:10/10/2008)... PLEASANTON, Calif., Oct. 10 /- Tr...as been authorized to affix the CE (Conformite,Eur...ntares(TM) Coronary,Stent System, a unique main ve... near coronary bifurcations., Representing the ne...(TM) system has potential use in a quarter of the ...
(Date:10/9/2008)... World Sight Day 2008 focuses on the need to pr.... 9 /- Of the 45 million people world...d three-quarters of them could,have avoided their ...reated., To view the Multimedia News Release, go ... Alcon, the world,s leader in eye care products an...
(Date:10/9/2008)... Top Line Clinical Results Expected in November...ll/ -- SCOLR Pharma, Inc.,(Amex: DDD ) announced ...ing,for the third of its three pivotal trials to e... of 12-hour extended-release (ER) ibuprofen for,th...ts to report top-line,results from this pivotal tr...
Breaking Medicine Technology:Inverness Medical Innovations Participates in Meeting on HIV/AIDS with UN Secretary-General 2Inverness Medical Innovations Participates in Meeting on HIV/AIDS with UN Secretary-General 3TriReme Medical Inc. Receives CE Marking for Antares(TM) Coronary Stent System 2ORBIS and Alcon Call Attention to the Aging Eye 2ORBIS and Alcon Call Attention to the Aging Eye 3SCOLR Pharma Announces Completion of Patient Enrollment and Dosing for Pivotal Clinical Trial Evaluating Extended Release Ibuprofen 2SCOLR Pharma Announces Completion of Patient Enrollment and Dosing for Pivotal Clinical Trial Evaluating Extended Release Ibuprofen 3Amsterdam Molecular Therapeutics to Appoint George Morstyn to Supervisory Board 4343 1Amsterdam Molecular Therapeutics to Appoint George Morstyn to Supervisory Board 4343 2Amsterdam Molecular Therapeutics to Appoint George Morstyn to Supervisory Board 4343 3EntreMed Commences Continuous Dosing Clinical Trial For MKC 1 1672 1EntreMed Commences Continuous Dosing Clinical Trial For MKC 1 1672 2EntreMed Commences Continuous Dosing Clinical Trial For MKC 1 1672 3EntreMed Commences Continuous Dosing Clinical Trial For MKC 1 1672 4China Bionanometer Industries 28CBIU 29 Describes their Current Production Capacity and Product Lines 15734 1China Bionanometer Industries 28CBIU 29 Describes their Current Production Capacity and Product Lines 15734 2Massachusetts Health Quality Partners Issues 2008 Report on Quality of Care 15732 1Massachusetts Health Quality Partners Issues 2008 Report on Quality of Care 15732 2Massachusetts Health Quality Partners Issues 2008 Report on Quality of Care 15732 3Massachusetts Health Quality Partners Issues 2008 Report on Quality of Care 15732 4Massachusetts Health Quality Partners Issues 2008 Report on Quality of Care 15732 5Massachusetts Health Quality Partners Issues 2008 Report on Quality of Care 15732 6
...TTLE--(BUSINESS WIRE)--Apr 19, 2007 - Gilead Scien...esults of its Phase III,AIR-CF2 study evaluating a...patients with cystic fibrosis (CF) who have,pulmon... study, a,28-day treatment course of aztreonam lys...haled or intravenous (IV) antibiotics versus,place...
...VER--(BUSINESS WIRE)--Apr 23, 2007 - Ceragenix Pha...al company focused on,infectious disease and derma...rch paper on two of the Company,s antimicrobial,co...he April issue,of the Journal of Antimicrobial Age...rnal of the American Society of,Microbiology, dedi...
Other Medicine Technology:Gilead Announces Presentation of Positive Phase III Data on,Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis 2Gilead Announces Presentation of Positive Phase III Data on,Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis 3Gilead Announces Presentation of Positive Phase III Data on,Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis 4Gilead Announces Presentation of Positive Phase III Data on,Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis 5Gilead Announces Presentation of Positive Phase III Data on,Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis 6Gilead Announces Presentation of Positive Phase III Data on,Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis 7Ceragenix Announces New Publication of Scientific Research on,Ceragenin Technology 2Ceragenix Announces New Publication of Scientific Research on,Ceragenin Technology 3Ceragenix Announces New Publication of Scientific Research on,Ceragenin Technology 4
(Date:10/13/2008)...eading Content Rights Management System, Supports... Content Spend, WEST CHESTER, Pa., Oct. 13 /PRNew...ding global pharmaceutical manufacturer has integr...primary platform for the,secure distribution, data...cs for their new product video content. Imperium i...
(Date:10/13/2008)...swire/ -- The National Coalition for,Quality Color...ncerns over,the National CT Colonography Study pub...Medicine. The evidence must be closely evaluated, ...y is not without significant,potential risks. The ...py,remains the "Gold Standard" for colorectal canc...
(Date:10/13/2008)...blem in daily life, survey shows, PORTLAND, Ore.,...three-quarters of people living with psoriasis say...e, according to a National Psoriasis,Foundation 20...viduals with psoriasis and psoriatic arthritis,als...ly lives, shapes their,feelings about themselves a...
(Date:10/13/2008)...swire/ -- During the Pri-Med New York,conference a...are providers,took a 20-question quiz prepared by ...n Somerset, NJ. The quiz tested basic knowledge of..., EMR software, and healthcare,administration., T... The average number,of correct answers was only 7....
Breaking Medicine News(10 mins):Health News:Global Pharma Integrates Imperium(TM) to Support Launch Content ROI Initiatives! 2Health News:National Coalition for Quality Colorectal Cancer Screening and Care Conveys Concerns over CT Colonography 2Health News:National Coalition for Quality Colorectal Cancer Screening and Care Conveys Concerns over CT Colonography 3Health News:National Psoriasis Foundation Releases 2008 Study Results 2Health News:MTBC Practice Management Quiz Sends Message to Doctors: There is Real Room for Improvement or a Need to Outsource 2
...hearts from donors 50 years of age and older appea... younger patients, according to a University Of Al...e Journal of Cardiac Surgery, March-April 200...d the results of using heart donors 50 years of ag...
...esearchers has highlighted that most of the US men...equired// for follow up tests done to evaluate the...6 men who underwent vasectomy at the Cleveland Cli...o attend the two-sets of sperm-checking tests, tha...
...plying antiviral coating on bank notes, vending ma...n fighting the epidemics//. Materials researcher ...ondon, has discovered a coating of metal, metal ox...strong antiviral properties, reported the online e...
...te by goths — a group fascinated by the darker sid...rm and suicide attempts//. University of Glasgo... young adults several times throughout their teen ...ens who said they were goths admitted to self-harm...
Other Medicine News:Health News:Men Unaware of Fertility Status After Vasectomy 2
Gentamicin Reagent Solution (10 mg/ml) liquid
LB Agar plates with 0.1mM EDTA.
Luria bertani broth: 1.0% Tryptone, 0.5% Yeast Extract, 1.0% Sodium Chloride.
2.5% Soytone, 4.8% Yeast Extract, 0.025% Magnesium Sulfate, 130mM Calcium Chloride.
Medicine Products: